0001048477-26-000008
SEC filingBioMarin reported Q1 FY2026 revenue growth of 2.8% to $766.2M, driven by higher sales volume for BRINEURA and VOXZOGO, partially offset by lower ALDURAZYME and ROCTAVIAN sales; however, operating income declined 42.1% to $129.6M due to higher G&A, including pre-close costs related to the Amicus acquisition.
Revenue for Q1 FY2026 was $766.2M, an increase of 2.8% compared to $745.1M in Q1 FY2025. This growth was driven by higher sales volume for BRINEURA — due to new patients initiating therapy across all regions and timing of orders in countries that place large government orders — and VOXZOGO — reflecting new patients initiating therapy across all regions. These increases were partially offset by lower sales volume for ALDURAZYME, attributable to timing of order fulfillment to Sanofi, and lower sales volume for ROCTAVIAN following the company’s voluntary withdrawal of the product from the market announced in the first quarter of 2026.
Gross profit was $571.2M, a decrease of 3.8% from $593.6M in Q1 FY2025. Gross margin was 74.6% for Q1 FY2026. Cost of Sales includes raw materials, personnel and facility and other costs associated with manufacturing commercial products. No specific charge or adjustment impacting gross margin is supported by the authoritative financial packet or business context.
Operating income was $129.6M, a decline of 42.1% from $223.9M in Q1 FY2025. The increase in G&A expense for the three months ended March 31, 2026, as compared to the same period in 2025, was primarily due to incremental administrative costs related to ongoing support of corporate initiatives and pre-close costs related to the Amicus acquisition. No quantification of SG&A or its components is supported beyond this qualitative driver.
Net income was $105.5M, down 43.2% from $185.7M in Q1 FY2025. Diluted EPS was $0.54, compared to $0.95 in the prior-year quarter — a 43.2% decline. The decrease reflects lower operating income and consistent tax treatment, with no unsupported adjustments to tax provision or share count disclosed.